The effectiveness of surveillance to identify extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) carriers is controversial during a non-outbreak situation. We performed additional stool cultures for ESBL-E among intensive care unit (ICU) patients already under active surveillance by means of sputum and urine cultures. We aimed to assess the efficacy of stool cultures for screening for ESBL-E in a non-outbreak situation. Methods: We conducted a retrospective cohort study in an ICU. Sputum and urine samples were cultured for ESBL-E surveillance purposes from January to September 2013 (phase 1). Stool cultures were routinely performed in addition from January to September 2014 (phase 2). Antimicrobial use density values and clinical outcomes were investigated and compared between phase 1 and 2. Results: We identified 512 and 478 patients in phase 1 and phase 2, respectively. ESBL-E were found in the feces of 65 (13.6%) patients in phase 2. The antimicrobial use density values (expressed as defined daily doses per 1,000 bed-days) were not significantly different between the two phases for fluoroquinolones (7 vs. 10, p = 0.376), third-generation cephalosporins (24.2 vs. 29.5, p = 0.724), tazobactam/piperacillin (44.6 vs. 57.3, p = 0.489), and carbapenems (73 vs. 55.5, p = 0.222). Moreover, there were no significant differences in ICU mortality and length of stay (11.5% vs. 9.8%, p = 0.412, and 9 vs. 10 days, p = 0.28, respectively). Conclusions: Stool culture seemed ineffective in improving the antimicrobial use density of broad-spectrum antimicrobials, clinical outcomes, and ICU length of stay, and is not recommended for surveillance of ESBL-E in a non-outbreak situation.
Introduction
Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are important because few antibiotics are effective against these pathogens. Moreover, clinical outcomes of patients with ESBL-E infections are poorer, with higher mortality and decreased clinical response rates compared with susceptible Enterobacteriaceae. [1] However, the effectiveness of surveillance for ESBL-E carriage, particularly in the absence of an outbreak, remains controversial. Past studies showed that the effectiveness of surveillance for preventing ESBL-E cross-transmission was limited. [2, 3] However, other studies showed prior cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. controlled. In addition, pilot surveillance for ESBL-E carriage by means of stool cultures was conducted over a 9-month period. We therefore conducted a retrospective cohort study to evaluate the clinical influence of this surveillance strategy during a non-outbreak situation in an adult ICU population.
Materials and Methods
This retrospective, single-center, observational study The medical records were reviewed to investigate patient characteristics. Surveillance-culture data, antimicrobial use density (AUD) values, the incidence of ESBL-E infections, the initial empirical antibiotic choice for patients with ESBL-E infections, ICU mortality, and ICU length of stay (LOS) for the described periods were evaluated. These parameters were compared between phase 1 and phase 2. Moreover, we grouped the patients of phase 2 into ESBL-E carriers and non-carriers, and the incidence of ESBL-E infections, ICU mortality rates, and ICU LOS were compared between these two groups.
To screen for ESBL production, all cultures were performed on selective media (CHROMagar TM ESBL, Kanto Chemical Co., Tokyo, Japan). Isolated bacteria were cultured and subjected to identification and antimicrobial susceptibility testing using the VITEK-2 ® automated microbiology system (Sysmex-bioMerieux, Tokyo, Japan University, Saitama, Japan), [9] which is a graphical user interface for the R software program (The R Foundation for Statistical Computing, Vienna, Austria). Continuous data were expressed as the median and interquartile range.
Statistical differences between two groups were determined using the Mann-Whitney U-test or the chi-squared test, as appropriate. All tests were two-tailed, and p values of <0.05 were considered statistically significant.
Results
We identified 512 and 478 patients in phases 1 and 2, respectively ( In addition, the incidence of ESBL-E infections (0.6% vs. 0.8%, p = 0.717), ICU mortality (11.5% vs. 9.8%, p = 0.412), and ICU LOS (9 days vs. 10 days, p = 0.28)
were not significantly different between two phases of the study (Table 2 ). There was no significant difference in the initial empiric antibiotic choice for patients with ESBL-E infections between two phases ( Table 3) .
The comparison between ESBL-E carriers and noncarriers in phase 2 is shown in Table 4 . The incidence of ESBL-E infections among ESBL-E carriers and ICU LOS were significantly higher and longer than among non-carriers (4.6% vs. 0.2%, p = 0.009, and 18.5 days vs. 9 days, p < 0.001, respectively), but ICU mortality (9.2% vs. 9.9%, p = 1.000) was not different.
Discussion
In this retrospective study, we attempted to evaluate the clinical benefit, which included evidence of improve- Data are presented as n (%) or median (interquartile range). M: male; F: female; APACHE: acute physiology and chronic health evaluation; MRSA: methicillin-resistant Staphylococcus aureus; MDRP: multidrug-resistant Pseudomonas aeruginosa; MDRAB: multidrug-resistant Acinetobacter baumannii; CRE: carbapenem-resistant Enterobacteriaceae; ESBL-E: extended-spectrum betalactamase-producing Enterobacteriaceae. *Sepsis was diagnosed based on evidence of infection along with the presence of systemic inflammatory response syndrome. † Definition of MDRP and MDRAB were defined as strains that were resistant to imipenem (MIC ≥ 16 μg/mL), amikacin (MIC ≥ 32 μg/mL), and ciprofloxacin (MIC ≥ 4 μg/mL), respectively.
empiric treatment of sepsis may be made according to the patient's clinical severity, and might not be influenced by
ESBL-E carriage surveillance information. Furthermore, the information of ESBL-E carriage surveillance had no benefit in terms of improving ICU mortality and ICU LOS in the present study.
The present study showed that the prevalence of gastrointestinal carriage of ESBL-E in ICU patients during a non-outbreak situation was 13.6%. ESBL-E colonization rates among ICU patients range from 2.2% in the Unites States [11] to 49.0% in India, [12] with geographical differences observed globally. [13] Previous Japanese studies have reported the prevalence of ESBL-E carriage to be 6.4% in healthy adults, [14] and 12% in pediatric tertiary care hospital patients. [15] In addition, a study in Spain reported that the prevalence of ESBL-E carriage was 3.7% in healthy volunteers, 5.5% in outpatients, and 12% in hospitalized patients. [16] As already reported, previous antibiotic use is a major risk factor for rectal carriage of ESBL-producing bacteria. [17, 18] Thus, the prevalence of ESBL-E carriage may be higher in hospitalized patients, as they are more likely to have received antibiotic therapy.
ICU mortality did not differ significantly between ES-
BL-E carriers and non-carriers in phase 2. However, the incidence of ESBL-E infections among ESBL-E carriers and ICU LOS were significantly higher and longer than among non-carriers. Several studies have shown that a long hospital stay is one of the risk factors for ESBL-E colonization [12, 18, 19] ; this was reflected in the present study findings. Furthermore, previous studies reported colonization with ESBL-E was a risk factor for subsequent ESBL infections [2, 5] and that the ESBL infections rates in colonized ICU patients ranged from 4.9% [19] to 68.8% [20] ; the results of the present study are in accordance with these previous studies. Another study reported that carriage of ESBL-E persisted for 12 months after having had an infection. [21] Thus, although intestinal ESBL-E colonization surveillance did not influence the clinical decision-making or outcomes in this study, it may be useful for treatment decisions for subsequent infections in ESBL-E carriers (for example, subsequent hospitalization for urosepsis). Further studies are needed to confirm the effects of active surveillance for ESBL-E carriage in several situations.
The present study has some limitations. First, it was a retrospective study involving a single center with a small sample size. Second, because surveillance of ESBL-E car- Data are presented as n (%). ESBL-E: extended-spectrum beta-lactamase-producing Enterobacteriaceae. Data are presented as n (%) or median (interquartile range). AUD: antimicrobial use density; DDD: defined daily dose; ESBL-E: extended-spectrum beta-lactamase-producing Enterobacteriaceae; ICU: intensive care unit; LOS: length of stay.
riage was performed using noninvasive procedures, we could not collect specimens at a fixed interval using rectal swab cultures. Furthermore, we were unable to evaluate the transmission rate, bacterial strains, or ESBL genes.
In conclusion, our study demonstrated that the performance of routine stool cultures for ESBL-E in ICU patients during a non-outbreak situation seemed to be ineffective in improving the AUD of broad-spectrum antimicrobials, clinical patient outcomes, and ICU LOS. Further studies are needed to determine the efficacy of active surveillance for intestinal colonization with ESBL-E. 
